Correlation between serum Urocortin-1 and α-Enolase in endometriosis: insights into a potential stress–metabolism signalling axis

In: Middle East Fertility Society Journal · 2026 · vol. 31(1) · doi:10.1186/s43043-026-00338-w · W7226021035
OA: diamond CC0
⚙ AI-generated summary by qwen3.7-flash, 2026-11-16 ⓘ

Serum Urocortin-1 and alpha-enolase levels were elevated in endometriosis patients with a strong positive correlation, indicating co-regulation within a potential stress-metabolism axis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-11-16 · read from full text ⓘ

This prospective cross-sectional study measured serum levels of Urocortin-1, alpha-enolase, and MMP-9 in 60 women with laparoscopically confirmed endometriosis compared to 60 controls undergoing surgery for benign non-endometriotic indications. The results showed significantly elevated levels of all three biomarkers in patients, with a very strong positive correlation (r = 0.91) between UCN-1 and ENO1 suggesting co-regulation within a stress–metabolism axis. While the combined panel achieved an AUC of 0.717, the authors noted that this performance falls below clinically deployable thresholds and emphasized the need for external validation before any clinical adoption can be considered. This paper is centrally about endometriosis — specifically investigating serum biomarkers and their correlations to understand disease pathobiology and diagnostic potential.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Abstract Background Endometriosis affects approximately 10% of women globally, with diagnostic delays often exceeding 8 years. Urocortin-1 (UCN-1) and alpha-enolase (ENO1) have each been independently implicated in its pathobiology, but their co-regulatory relationship in circulation remains poorly understood. This study aimed to quantify serum UCN-1, ENO1, and MMP-9 in patients versus controls, characterise the ENO1–UCN-1 correlation, and evaluate the independent diagnostic contribution of these biomarkers. Results Principal biomarkers were significantly elevated in patients (MMP-9: p = 0.015; ENO1: p = 0.040; UCN-1: p = 0.021). A pivotal finding was the very strong positive correlation between serum ENO1 and UCN-1 ( r = 0.91, 95% CI 0.853–0.945; p < 0.001), suggesting strong co-regulation. Both markers exhibited significant stage-dependent escalation ( p < 0.001). In multivariate logistic regression adjusted for age and BMI, UCN-1 emerged as a strong independent predictor (aOR = 4.564; 95% CI: 1.083–19.227; p = 0.039), while ENO1 was not independently predictive (aOR = 0.868; p = 0.451) due to high collinearity with UCN-1 (VIF = 5.82). The combined panel (UCN-1 + ENO1 + MMP-9) achieved AUC = 0.717 (bootstrap-corrected 0.701; 95% CI 0.611–0.789). Conclusions The r = 0.91 correlation provides preliminary serum-level evidence consistent with a hypothesised stress–metabolism axis, in which UCN-1-mediated signalling may be associated with glycolytic reprogramming (ENO1), putatively via PI3K–Akt and HIF-1α, although the intracellular steps were not measured in this study and the cascade remains hypothesis-generating only. ENO1 is not an independent biomarker of endometriosis in this dataset; its apparent contribution is fully captured by UCN-1 due to strong co-regulation. The combined UCN-1/ENO1/MMP-9 panel is NOT ready for clinical use: the AUC of 0.717 falls well below clinically deployable thresholds (typically AUC ≥ 0.85–0.90), and prospective external validation in larger, multi-centre cohorts — together with direct mechanistic confirmation — is mandatory before any clinical adoption can be considered.
Full text 41,698 characters · extracted from oa-html · 11 sections · click to expand

Abstract

Background Endometriosis affects approximately 10% of women globally, with diagnostic delays often exceeding 8 years. Urocortin-1 (UCN-1) and alpha-enolase (ENO1) have each been independently implicated in its pathobiology, but their co-regulatory relationship in circulation remains poorly understood. This study aimed to quantify serum UCN-1, ENO1, and MMP-9 in patients versus controls, characterise the ENO1–UCN-1 correlation, and evaluate the independent diagnostic contribution of these biomarkers.

Results

Principal biomarkers were significantly elevated in patients (MMP-9: p = 0.015; ENO1: p = 0.040; UCN-1: p = 0.021). A pivotal finding was the very strong positive correlation between serum ENO1 and UCN-1 (r = 0.91, 95% CI 0.853–0.945; p < 0.001), suggesting strong co-regulation. Both markers exhibited significant stage-dependent escalation (p < 0.001). In multivariate logistic regression adjusted for age and BMI, UCN-1 emerged as a strong independent predictor (aOR = 4.564; 95% CI: 1.083–19.227; p = 0.039), while ENO1 was not independently predictive (aOR = 0.868; p = 0.451) due to high collinearity with UCN-1 (VIF = 5.82). The combined panel (UCN-1 + ENO1 + MMP-9) achieved AUC = 0.717 (bootstrap-corrected 0.701; 95% CI 0.611–0.789).

Conclusions

The r = 0.91 correlation provides preliminary serum-level evidence consistent with a hypothesised stress–metabolism axis, in which UCN-1-mediated signalling may be associated with glycolytic reprogramming (ENO1), putatively via PI3K–Akt and HIF-1α, although the intracellular steps were not measured in this study and the cascade remains hypothesis-generating only. ENO1 is not an independent biomarker of endometriosis in this dataset; its apparent contribution is fully captured by UCN-1 due to strong co-regulation. The combined UCN-1/ENO1/MMP-9 panel is NOT ready for clinical use: the AUC of 0.717 falls well below clinically deployable thresholds (typically AUC ≥ 0.85–0.90), and prospective external validation in larger, multi-centre cohorts — together with direct mechanistic confirmation — is mandatory before any clinical adoption can be considered. Graphical Abstract Similar content being viewed by others

Background

Endometriosis is a chronic oestrogen-dependent inflammatory disorder characterised by the presence of endometrium-like tissue outside the uterine cavity, predominantly on the peritoneum, ovaries, and rectovaginal septum [1]. The Lancet recently described it as the “missed disease”, affecting 10% of women of reproductive age globally — approximately 190 million individuals — and noted that standards of care remain “unacceptably poor” [2]. Diagnostic delay averages 6.8 years across international cohorts (1.5–11.4 years) [3], with delays of 10–12 years reported in some populations [4], underscoring the particular need for non-invasive diagnostic tools in Middle Eastern and resource-limited health systems. The pathobiology of endometriosis is multidimensional, encompassing peritoneal inflammation, immune dysregulation, neuroangiogenesis, extracellular matrix (ECM) invasion, and neuroendocrine stress-axis activation [5]. CA-125 (MUC16) has been most extensively studied but achieves limited sensitivity for early-stage disease [6, 7], while emerging proteomic and microRNA-based platforms [8, 9] demonstrate superior accuracy but require mass spectrometry or next-generation sequencing equipment unavailable in most clinical settings. This evidence gap reinforces the continued need for serum ELISA-based biomarker panels that are both mechanistically grounded and practically deployable. Metabolic reprogramming — specifically the shift from oxidative phosphorylation to aerobic glycolysis (the Warburg effect) driven by hypoxia-inducible factor-1α (HIF-1α) — is now recognised as a central driver of ectopic lesion survival and progression in endometriosis [10, 11]. A 2025 review (Kim et al.) characterised the roles of HIF-1α signalling, the PI3K–Akt–mTOR pathway, and inflammatory cytokines in driving glycolytic gene programs in endometriotic stromal cells [10]. Concurrently, endometriosis is recognised as a disease of chronic neuroendocrine stress-axis dysregulation, in which corticotropin-releasing factor (CRF) superfamily peptides modulate peritoneal inflammation, immune evasion, and nociception [12]. Urocortin-1 (UCN-1) is a 40-amino-acid neuropeptide of the CRF superfamily that binds CRFR1 and CRFR2 with high affinity, integrating systemic stress responses with local pelvic inflammation [13, 14]. Abramiuk et al. (2023) demonstrated that serum UCN-1 is significantly upregulated in endometriosis patients and tracks with advanced disease stages [15, 16]. α-Enolase (ENO1) is a multifunctional glycolytic enzyme that catalyses the conversion of 2-phosphoglycerate to phosphoenolpyruvate. In Warburg-like reprogramming, ENO1 is upregulated by HIF-1α to sustain the bioenergetic demands of rapidly proliferating ectopic cells [17, 18]. Beyond glycolysis, ENO1 translocates to the cell surface where it acts as a plasminogen receptor, concentrating plasmin generation at the pericellular surface [19]. Plasminogen activation is critical for the proteolytic cleavage of pro-matrix metalloproteinases, particularly MMP-9, thereby facilitating ECM degradation and lesion invasion [20, 21]. While UCN-1 (stress axis), ENO1 (metabolic axis), and MMP-9 (invasive axis) have each been independently implicated in endometriosis [22,23,24], their co-regulatory dynamics in peripheral blood remain uncharacterised. Mechanistic links between CRF-receptor activation, PI3K–Akt signalling, HIF-1α stabilisation, and ENO1 transcription are increasingly described in non-endometriosis systems and are detailed in the Discussion. However, this proposed stress–metabolism signalling axis remains a hypothesis-generating model and has not been evaluated clinically in endometriosis cohorts. Therefore, this study aimed to: (1) quantify serum levels of UCN-1, ENO1, and MMP-9 in women with laparoscopically confirmed endometriosis versus controls; (2) investigate the correlation between these neuroendocrine and metabolic markers; and (3) evaluate their independent and combined diagnostic utility.

Methods

Study design and participants This prospective cross-sectional study was conducted at the Department of Chemistry and Biochemistry, College of Medicine, University of Babylon, Iraq, from September 2025 to March 2026. The study protocol was approved by the Institutional Ethics Committee of the College of Medicine, University of Babylon (Ref. No. 5/65, September 18, 2025), and written informed consent was obtained from all participants prior to enrolment, in strict accordance with the Declaration of Helsinki. The study enrolled 120 women of reproductive age (18–45 years) who were scheduled for diagnostic or therapeutic laparoscopy at the Maternity and Children Teaching Hospital in Babylon, the Maternity and Obstetrics Hospital in Karbala, and Al-Kafeel Super Speciality Hospital. The sample size of 60 per group was determined using G*Power software (v3.1.9.7) [25] based on an a priori power analysis for an independent samples t-test. To detect a medium effect size (Cohen’s d = 0.55) [26] with 80% power (1-β) at a two-sided α = 0.05, a minimum of 53 participants per group was required; this was increased to 60 per group to allow for pre-analytical exclusions. For the primary correlation outcome, n = 60 patients yields a 95% CI of approximately 0.85–0.95 around the observed r = 0.91. Stage-stratified subgroup analyses (n = 18–24 per stage) are inherently more limited in power; their stage-specific correlation coefficients are therefore reported with full 95% confidence intervals and individual p-values, and inter-stage differences are interpreted with caution (see Results). The patient group (n = 60) comprised women with laparoscopically and histopathologically confirmed endometriosis. Disease severity was classified according to the revised American Society for Reproductive Medicine (rASRM) staging system during surgery: Stages I–II (mild/moderate; n = 24), Stage III (severe; n = 18), and Stage IV (very severe; n = 18). The control group (n = 60) consisted of age- and BMI-matched women who underwent laparoscopy for benign non-endometriotic indications (unexplained infertility, tubal ligation, or benign ovarian cysts). The absence of endometriosis in controls was determined through systematic visual inspection of the pelvis and peritoneum during laparoscopy; histological confirmation of “endometriosis-free” status was not performed [27]. Microscopic disease could therefore be present in some controls, which would bias the patient-versus-control comparisons toward the null (i.e., attenuate the observed effect sizes rather than inflate them) and underestimate true between-group differences in serum biomarker levels. This limitation is discussed quantitatively in the Limitations section. Exclusion criteria for both groups included adenomyosis, polycystic ovary syndrome (PCOS), pelvic inflammatory disease, uterine fibroids, current pregnancy, history of gynaecological malignancies, autoimmune disorders, and use of hormonal therapies (oral contraceptives, GnRH agonists, or progestins) within the three months preceding surgery. Inclusion criteria, applied identically to both groups, were: female sex, age 18–45 years, regular menstrual cycles (21–35 days) at recruitment, willingness to provide written informed consent, and a scheduled laparoscopy at one of the three participating centres. Menstrual cycle phase and detailed circulating hormonal profiles (estradiol, progesterone, sex-hormone-binding globulin) were not systematically recorded; given that both UCN-1 and MMP-9 are known to vary across the menstrual cycle, this is acknowledged as a major limitation of the present design (see Limitations). Blood sampling and biochemical assays Fasting venous blood samples (5 mL) were collected from all participants preoperatively. Samples were allowed to clot at room temperature for 30 min, followed by centrifugation at 3,000 rpm for 15 min. Separated serum was immediately aliquoted into sterile Eppendorf tubes and stored at − 80 °C until biochemical analysis to prevent multiple freeze-thaw cycles. Serum concentrations of the target biomarkers were quantified using highly sensitive sandwich Enzyme-Linked Immunosorbent Assay (ELISA) kits manufactured by Bioassay Technology Laboratory (BT LAB), Shanghai, China, according to the manufacturer’s strict protocols. The specific kits used were: (1) Human Urocortin (UCN) ELISA Kit (Cat. No. E1406Hu; sensitivity = 0.01 ng/mL; standard curve range = 0.05–10 ng/mL); (2) Human α-Enolase (ENO1) ELISA Kit (Cat. No. E4933Hu; sensitivity = 0.048 ng/mL; standard curve range = 0.1–40 ng/mL); and (3) Human Matrix Metalloproteinase 9/Gelatinase B (MMP-9) ELISA Kit (Cat. No. E0936Hu; sensitivity = 15.12 ng/L; standard curve range = 30–9,000 ng/L). All assays were performed in duplicate, with absorbance read at 450 nm. Intra- and inter-assay coefficients of variation (CV) were: UCN-1, 4.7% / 6.8%; ENO1, 5.2% / 7.4%; MMP-9, 5.9% / 8.1% (all within manufacturer specifications). In-house spike-and-recovery experiments confirmed 96–104% recovery across the working range, and in-house cross-reactivity tests using high-concentration spikes of non-target proteins (5- to 50-fold above expected serum levels) produced apparent signals below each kit’s lower limit of detection (Supplementary Tables S1, S2). In addition, the manufacturer’s datasheet for the UCN-1 ELISA kit (BT LAB E1406Hu) reports no detectable cross-reactivity with structurally related CRF-family peptides (CRH, urocortin-2, urocortin-3) at concentrations up to 100 ng/mL; the ENO1 kit datasheet reports no detectable cross-reactivity with γ-enolase or β-enolase isoforms. These manufacturer specifications, together with our in-house data, exclude antibody cross-reactivity as an explanation for the observed inter-marker correlations. UCN-1, ENO1, and MMP-9 are also structurally distinct proteins (a 40-amino-acid neuropeptide, a 433-amino-acid glycolytic enzyme, and a 707-amino-acid zinc-dependent endopeptidase, respectively). Statistical analysis Data analysis was performed using SPSS Statistics version 26.0 (IBM Corp., Armonk, NY, USA). Normality of continuous variables was assessed by Shapiro–Wilk test. Normally distributed data are presented as mean ± SD and compared by independent samples Student’s t-test. Categorical variables are presented as frequencies (percentages) and compared by χ² test. One-way ANOVA followed by Tukey’s post-hoc test was used to compare biomarker levels across rASRM stages, with post-hoc statistical power calculated to confirm adequacy for between-stage mean differences. Pearson’s correlation coefficient (r) was used to evaluate linear relationships, with 95% confidence intervals derived via the Fisher z-transform and exact two-sided p-values reported for each subgroup correlation. Multivariate binary logistic regression with disease status as the dependent variable adjusted for age and BMI [28]. Adjusted odds ratios (aOR) with 95% confidence intervals were reported. Multicollinearity was formally assessed by variance inflation factor (VIF) and tolerance, with VIF > 5 indicating moderate and VIF > 10 indicating severe collinearity [28]. Three sequential models were examined to document collinearity-driven effects: ENO1 alone (with age and BMI), UCN-1 alone (with age and BMI), and both biomarkers together. Goodness-of-fit was evaluated using the Hosmer–Lemeshow test (p > 0.05 indicating adequate fit). Receiver operating characteristic (ROC) analysis was performed to assess diagnostic value, with AUC values reported alongside bootstrap-derived standard errors and 95% confidence intervals. Internal validation used bootstrap resampling with 1,000 iterations to derive bias-corrected (optimism-adjusted) AUC estimates. A p-value < 0.05 was considered statistically significant.

Results

Demographic and clinical characteristics The groups were comparable for age (31.22 ± 8.88 vs. 30.50 ± 6.87 years; p = 0.663) and BMI (27.0 ± 3.93 vs. 28.5 ± 4.15 kg/m2; p = 0.065), confirming adequate matching. Dysmenorrhoea was the dominant clinical feature among patients (87.0% vs. 25.0%; p < 0.001); family history (18.3% vs. 0.0%; p = 0.001), marital status (76.7% vs. 43.3% married; p = 0.001), and nulliparity (63.3% vs. 40.0%; p = 0.021) also differed significantly (Table 1). Serum biomarker levels All three principal biomarkers were significantly elevated in patients (Table 2). UCN-1 was elevated (1.58 ± 0.71 vs. 1.33 ± 0.32 ng/mL; p = 0.021), MMP-9 was elevated (842.1 ± 218.7 vs. 759.9 ± 124.7 ng/L; p = 0.015), and ENO1 was elevated (6.39 ± 2.66 vs. 5.57 ± 1.16 ng/mL; p = 0.040). Stage-dependent biomarker escalation One-way ANOVA revealed progressive escalation of all three markers across rASRM stages (Table 3; Fig. 1). ENO1 showed the steepest relative increase (81% from Stage I–II to Stage IV; p < 0.001), followed by MMP-9 (p = 0.001) and UCN-1 (p < 0.001). Post-hoc power was ≥ 98% for all three markers (Cohen’s f = 0.64–0.77, large effects). Correlation analysis Pearson correlation analysis in the patient group revealed the central finding of this study: a very strong positive correlation between serum ENO1 and UCN-1 (r = 0.910, 95% CI 0.853–0.945; p < 0.001; n = 60). Stage-stratified Pearson coefficients with confidence intervals and exact p-values were as follows: Stages I–II r = 0.69 (95% CI 0.40–0.86; p < 0.001; n = 24); Stage III r = 0.57 (95% CI 0.14–0.82; p = 0.014; n = 18); Stage IV r = 0.91 (95% CI 0.77–0.97; p < 0.001; n = 18). The wide and overlapping confidence intervals across stages preclude any strong inference about differential strength of the correlation by stage; in particular, the apparently lower Stage III value (0.57) cannot be reliably distinguished from the Stages I–II value (0.69), as the 95% confidence intervals overlap substantially. Additional significant correlations included MMP-9 with ENO1 (r = 0.432; p = 0.001), MMP-9 with UCN-1 (r = 0.314; p = 0.017), and UCN-1 with BMI (r = 0.290; p = 0.030) (Table 4). Multivariate logistic regression analysis UCN-1 was the strongest independent predictor of endometriosis (aOR = 4.564; 95% CI 1.083–19.227; p = 0.039). MMP-9 retained independent significance (aOR = 1.003; 95% CI 1.000–1.006; p = 0.024). ENO1 did not achieve independent significance (aOR = 0.868; 95% CI 0.601–1.254; p = 0.451). VIF analysis confirmed moderate multicollinearity between ENO1 and UCN-1 (VIF = 5.82; tolerance = 0.172; Supplementary Table S3). Three sequential models (Supplementary Table S4) showed: ENO1 alone was significant (β = 0.164, p = 0.041); UCN-1 alone was a strong predictor (β = 1.518, p = 0.005); and in the combined model only UCN-1 remained significant. BMI showed a significant inverse association (aOR = 0.867; p = 0.013). The Hosmer–Lemeshow test indicated adequate fit (χ² = 12.94, df = 8, p = 0.114) (Table 5). ROC curve analysis Individual biomarker AUCs were: UCN-1 0.621 (sensitivity 85.0%; p = 0.021), MMP-9 0.648 (sensitivity 75.4%; p = 0.004), and ENO1 0.521 (p = 0.703; not significant) (Table 6; Fig. 2). The combined panel (UCN-1 + ENO1 + MMP-9) achieved AUC = 0.717 (bootstrap-corrected 0.701; p < 0.001), improving to 0.732 (bootstrap-corrected 0.715) with age and BMI (Full Model). All AUCs remain well below the AUC ≥ 0.85–0.90 range generally accepted as a clinically deployable diagnostic threshold; this panel is therefore NOT ready for clinical use as a standalone diagnostic, and prospective external validation in larger, multi-centre cohorts is mandatory before any clinical adoption can be considered.

Discussion

This study delivers five principal findings. First, all three candidate biomarkers (MMP-9, ENO1, UCN-1) were significantly elevated in endometriosis patients. Second, serum ENO1 and UCN-1 displayed an exceptional positive correlation (r = 0.91, 95% CI 0.853–0.945; p < 0.001), providing the first human circulating evidence consistent with a hypothesised co-regulatory stress–metabolism axis. Third, both ENO1 and UCN-1 escalated progressively across rASRM stages (p < 0.001 each). Fourth, multivariate logistic regression confirmed UCN-1 as the dominant independent predictor (aOR = 4.564; p = 0.039), while ENO1 lost independent significance due to high collinearity (VIF = 5.82) with UCN-1. Fifth, the combined panel achieved a moderately improved AUC of 0.732 (bootstrap-corrected 0.715), but remained well below clinical-deployment thresholds and is therefore NOT ready for clinical use. The Pearson correlation of r = 0.91 between serum ENO1 and UCN-1 is the study’s central finding. In the endometriosis biomarker literature, where most published inter-marker correlations range between r = 0.2 and r = 0.5, a value of r = 0.91 (R²=0.83) is exceptional. We considered the alternative hypothesis that this correlation reflected ELISA cross-reactivity or assay artefact, but several lines of evidence argue against this: (i) UCN-1 (40-aa) and ENO1 (433-aa) share no significant sequence or epitope homology; (ii) in-house spike-and-recovery yielded 96–104% recovery; (iii) in-house cross-reactivity tests with non-target proteins produced signals below the kits’ limits of detection (Supplementary Tables S1, S2); (iv) the manufacturer’s datasheets for both the UCN-1 and ENO1 BT LAB kits report no detectable cross-reactivity with structurally related family members (CRH and other urocortin paralogues for UCN-1; γ- and β-enolase isoforms for ENO1) at concentrations well above expected serum levels; and (v) stage-stratified within-group correlations (r = 0.57–0.91; Fig. 3) demonstrate that ENO1–UCN-1 co-variation persists across the disease-severity spectrum. The most parsimonious mechanistic explanation for this strong co-variation is a hypothesised cascade in which UCN-1 produced in the endometriotic microenvironment binds CRFR1/2 and activates PI3K–Akt signalling, leading to HIF-1α stabilisation and transcriptional activation of ENO1 via hypoxia response elements (Fig. 4). It must be emphasised that this cascade is correlation-supported only. UCN-1 produced in the endometriotic microenvironment binds CRFR1/2, activating PI3K–Akt and generating reactive oxygen species (ROS) [13, 29]. This pathway inhibits prolyl hydroxylases (PHD1/2/3), leading to stabilisation of HIF-1α [10, 30, 31], which then binds hypoxia response elements (HRE) in the ENO1 promoter to drive glycolytic transcription [18, 30]. Direct measurement of HIF-1α protein, PI3K–Akt activity, ROS, and CRFR1/2 expression was not performed in the present study; while the molecular literature supports each individual link in non-endometriosis systems, the integrated cascade has not been directly demonstrated in human endometriotic tissue and remains a hypothesis-generating model. Direct in-vitro experiments — for example, UCN-1 stimulation of endometriotic stromal cells with HIF-1α and ENO1 readouts — are required before any causal axis can be claimed. Evidence on miRNA–HIF-1α reciprocal regulation derives from cancer models [32] and has not yet been validated in endometriotic tissue. MMP-9 correlated significantly with both ENO1 (r = 0.432; p = 0.001) and UCN-1 (r = 0.314; p = 0.017), positioning it as a putative downstream effector of both the glycolytic axis and the neuroendocrine axis. The mechanistic link between ENO1 and MMP-9 is well established: cell-surface ENO1 binds plasminogen and facilitates its conversion to plasmin, which proteolytically activates pro-MMP-9 [17, 19]. A 2025 review in Biomedical Reports confirmed MMP-2 and MMP-9 as key effectors of ectopic endometrial cell migration and invasion [33]. Our MMP-9 results are consistent with the 2024 meta-analysis by Huang et al. [23], which pooled 15 studies and confirmed significantly higher blood MMP-9 in endometriosis patients (p < 0.0001) with stage-dependent elevation. MMP-9 showed no significant BMI dependency (p = 0.677) in our study, in contrast to BMI-sensitive ENO1 and UCN-1, suggesting MMP-9 activation is driven primarily by lesion-level plasmin and inflammatory protease activity rather than systemic adipokines [34]. The UCN-1 elevation (1.58 ± 0.71 vs. 1.33 ± 0.32 ng/mL; p = 0.021) is consistent with accumulating evidence for UCN-1 as a neuroendocrine–inflammatory biomarker. Abramiuk et al. (2023) [15] showed that serum UCN-1 elevation tracks with immune cell subset dysregulation, and Carrarelli et al. [29] demonstrated highest UCN-1 and CRFR2 mRNA expression in deep infiltrating endometriosis, mechanistically explaining why Stage IV patients in our cohort showed the highest serum UCN-1 (2.17 ± 1.06 ng/mL) with the widest variability. The serum ENO1 elevation (6.39 ± 2.66 vs. 5.57 ± 1.16 ng/mL; p = 0.040) was statistically significant but modest, reflecting the expected dilution of a primarily tissue-level glycolytic signal in peripheral blood. The non-significant standalone ROC AUC (0.521) is therefore not evidence against ENO1’s biological importance but a consequence of measuring a cell-compartmental metabolic adaptation systemically. Critically, ENO1 is not an independent biomarker of endometriosis in this dataset; its apparent diagnostic contribution is fully captured by UCN-1 because of strong co-regulation (VIF = 5.82). However, collinearity indicates shared variance, not causal direction: while our preferred interpretation is that UCN-1 sits upstream of ENO1 in the hypothesised cascade, it is equally consistent with these data that both biomarkers are co-regulated by an unmeasured upstream factor (for example, HIF-1α itself, or local hypoxia in the ectopic microenvironment [35]) without UCN-1 being the proximate driver. The present serum correlations therefore cannot prove that UCN-1 is the regulator and ENO1 the passenger; both may be parallel downstream readouts of a shared upstream programme. Our logistic regression revealed a significant inverse relationship between BMI and endometriosis risk (aOR = 0.867; p = 0.013). While counter-intuitive, this aligns with the meta-analysis by Yong et al. (2017) reporting pooled RR = 0.67 per 5 kg/m² increase [36] and Hediger et al. (2005) reporting a 12–14% decrease per unit BMI [37], aligning precisely with our 13.3%. The combined panel (UCN-1 + ENO1 + MMP-9) achieved AUC = 0.717 (bootstrap-corrected 0.701), reaching 0.732 (bootstrap-corrected 0.715) when adjusted for age and BMI. This represents a modest improvement over individual biomarkers but remains well below the AUC ≥ 0.85–0.90 range generally accepted as a clinically deployable diagnostic threshold. We therefore explicitly conclude that the present panel is NOT ready for clinical use as a standalone diagnostic. Comparable additive value has been reported by Xu et al. (2026) [38], where a CXCL12 + VEGF + CA-125 panel improved AUC from 0.626 to 0.882, and by Rokhgireh et al. (2020), where an enolase/Cr + CA-125 + CA19-9 panel reached AUC = 0.675 [39]. The present panel integrates biomarkers from three distinct mechanistic axes — neuroendocrine (UCN-1), metabolic (ENO1), and invasive (MMP-9) — and may have value within larger composite signatures rather than as a standalone test [40]. Integrating the serum correlation data with the 2023–2025 molecular literature, we propose the working — and explicitly hypothetical — model shown in Fig. 4. This model is supported by the present serum correlations and by published evidence for each individual link in non-endometriosis systems, but the integrated cascade has not been directly demonstrated in human endometriotic tissue. Each individual link is supported by published evidence in related systems; the full integrated cascade remains hypothesis-generating and requires in-vitro and tissue-level validation before clinical translation.

Limitations

Several limitations must be acknowledged. First, the single-institution design with n = 60 per group limits statistical power in stage subgroup analyses and restricts generalisability to non-Iraqi populations; external multi-centre replication is necessary. Second (a major limitation), HIF-1α — the proposed molecular hub of the axis — was not measured in this study. HIF-1α assay reagents requiring tissue lysates were not available at the participating sites at the time of recruitment, and stable serum quantification of HIF-1α in a manner consistent with our ELISA-based pipeline could not be performed reliably. Without direct HIF-1α measurement, the proposed CRF → PI3K–Akt → HIF-1α → ENO1 cascade remains an attractive but unvalidated mechanistic hypothesis; we have therefore framed Fig. 4 explicitly as a hypothesised model, and we consider direct HIF-1α measurement (serum and ideally lesion tissue) a necessary component of any prospective follow-up study designed to test the proposed axis [41,42,43]. Third (a major limitation), menstrual cycle phase and concurrent circulating sex-hormone profiles (estradiol, progesterone, sex-hormone-binding globulin) were not systematically recorded. Both UCN-1 and MMP-9 are known to vary across the menstrual cycle, with MMP-9 in particular tending to be elevated in the late luteal/perimenstrual phase. The absence of cycle-phase standardisation may therefore have introduced uncontrolled biological variability and contributed to the wide standard deviations seen at advanced disease stages. Retrospective cycle-phase data could not be reconstructed reliably for the present cohort; future prospective studies should standardise sampling to a single defined cycle phase (e.g., mid-follicular) and report concurrent hormonal profiles. Fourth, the cross-sectional design precludes longitudinal assessment of biomarker dynamics with treatment or recurrence. Fifth, ROC cut-offs were derived and evaluated within the same dataset, introducing optimism bias; we mitigated this with bootstrap-corrected AUC estimates (1,000 iterations), but prospective external validation remains mandatory. Sixth, the control group was defined by visual laparoscopic inspection without histological exclusion of microscopic endometriosis. Visual laparoscopic inspection alone has been reported to have a sensitivity of ~ 94% but a positive predictive value of only ~ 43–45% for detecting endometriosis when biopsy is used as the reference standard [44], implying that a small but non-negligible proportion of “controls” may harbour asymptomatic or microscopic disease. The direction of this bias is conservative: contamination of the control group with true endometriosis cases would attenuate (not inflate) the patient-versus-control differences in UCN-1, ENO1, and MMP-9, and would similarly attenuate the AUC estimates. The true between-group differences and diagnostic discrimination are therefore likely modestly underestimated in our data. Seventh, biomarker concentrations were measured exclusively in serum; parallel measurements in peritoneal fluid would provide a more direct reflection of the local pelvic microenvironment. Eighth, the absence of direct in-vitro experimentation means that the proposed CRF → HIF-1α → ENO1 cascade is inferred from convergent serum correlational data and published molecular biology in related systems; direct experimental confirmation in human endometriotic stromal cells (e.g., UCN-1 stimulation with HIF-1α / ENO1 readouts) is required before any clinical translation.

Conclusions

This study provides preliminary clinical evidence consistent with a hypothesised circulating stress–metabolism signalling axis in endometriosis, characterised by an exceptionally strong positive correlation (r = 0.91; 95% CI 0.853–0.945) between UCN-1 and ENO1. Both markers, along with MMP-9, are significantly elevated in patients and escalate progressively with rASRM stage. Collinearity-driven loss of ENO1 significance in multivariate analysis (VIF = 5.82), combined with the strong predictive power of UCN-1, supports the hypothesis that these molecules operate within a shared regulatory pathway rather than independently — although, as discussed, this does not by itself establish UCN-1 as the proximate driver, and a common upstream regulator remains an equally compatible interpretation. The combined panel achieved AUC = 0.732 (bootstrap-corrected 0.715). Critically, the absolute discrimination remains well below clinically deployable thresholds (AUC ≥ 0.85–0.90), and we explicitly state that the present UCN-1/ENO1/MMP-9 panel is NOT ready for clinical use as a standalone diagnostic. The panel represents a candidate, mechanism-informed direction for further development. Prospective external validation in larger, multi-centre cohorts — together with direct in-vitro and tissue-level confirmation of the proposed cascade, including HIF-1α measurement, and cycle-phase-standardised sampling — is required before any clinical translation can be considered, particularly for resource-limited settings with the most acute unmet need. Data availability The datasets generated and analysed during the current study are available from the corresponding author on reasonable request. Abbreviations - aOR: - Adjusted Odds Ratio - AUC: - Area Under the ROC Curve - BMI: - Body Mass Index - CI: - Confidence Interval - CRF: - Corticotropin-Releasing Factor - CRFR: - Corticotropin-Releasing Factor Receptor - CV: - Coefficient of Variation - ECM: - Extracellular Matrix - ELISA: - Enzyme-Linked Immunosorbent Assay - ENO1: - α-Enolase - HIF-1α: - Hypoxia-Inducible Factor-1 Alpha - HRE: - Hypoxia Response Elements - MMP-9: - Matrix Metalloproteinase-9 - PI3K: - Phosphoinositide 3-Kinase - rASRM: - Revised American Society for Reproductive Medicine - ROC: - Receiver Operating Characteristic - ROS: - Reactive Oxygen Species - SD: - Standard Deviation - SHBG: - Sex Hormone-Binding Globulin - UCN-1: - Urocortin-1 - VIF: - Variance Inflation Factor

References

Zondervan KT, Becker CM, Missmer SA, (2020) Endometriosis. N Engl J Med 382(13):1244–1256 Taylor HS, Kotlyar AM, Flores VA (2021) Endometriosis is a chronic systemic disease: clinical challenges and novel innovations. Lancet 397(10276):839–852 Fryer S, Roper J, Dilley J et al (2025) Diagnostic delay in endometriosis: a systematic review and meta-analysis. Hum Reprod Open 2025(2):hoaf015 Becker CM, Bokor A, Heikinheimo O et al (2022) ESHRE guideline: endometriosis. Hum Reprod Open 2022(2):hoac009 Bulun SE, Yilmaz BD, Sison C et al (2019) Endometriosis. Endocr Rev 40(4):1048–1079 Vodolazkaia A, El-Aalamat Y, Popovic D et al (2012) Evaluation of a panel of 28 biomarkers for the non-invasive diagnosis of endometriosis. Hum Reprod 27(9):2698–2711 Socolov R, Butureanu S, Anghelache-Lupascu I et al (2011) The value of serological markers in the diagnosis and prognosis of endometriosis: a literature review. Rom J Morphol Embryol 52(3 Suppl):1001–1006 Schoeman EM, Bringans S, Peters K et al (2025) Identification of plasma protein biomarkers for endometriosis (PromarkerEndo). Reprod Biomed Online 50(4):103–118 Bendifallah S, Suisse S, Puchar A et al (2025) Validation of a Salivary miRNA Signature of Endometriosis (Endotest). NEJM Evid 4(2):EVIDoa2400159 Kim BS, Kim B, Yoon S et al (2025) Warburg-like Metabolic Reprogramming in Endometriosis: From Molecular Mechanisms to Therapeutic Approaches. Pharmaceuticals 18(6):813 Young VJ, Brown JK, Saunders PT, Horne AW (2013) The role of the peritoneum in the pathogenesis of endometriosis. Hum Reprod Update 19(5):558–569 Anastasiu CV, Moga MA, Elena Neculau A et al (2020) Biomarkers for the Noninvasive Diagnosis of Endometriosis: State of the Art and Future Perspectives. Int J Mol Sci 21(5):1750 Grammatopoulos DK (2012) Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction. Br J Pharmacol 166(1):85–97 Florio P, Arcuri F, Ciarmela P et al (2002) Identification of urocortin mRNA and peptide in the human endometrium. J Endocrinol 173(2):R9–R14 Abramiuk M, Grywalska E, Malec-Milewska M et al (2023) Possible Correlation between Urocortin 1 (Ucn1) and Immune Parameters in Patients with Endometriosis. Int J Mol Sci 24(9):7787 Florio P, Reis FM, Torres PB et al (2007) Plasma urocortin levels in the diagnosis of ovarian endometriosis. Obstet Gynecol 110(3):594–600 Diaz-Ramos A, Roig-Borrellas A, Garcia-Melero A, Lopez-Alemany R (2012) α-Enolase, a multifunctional protein: its role in pathophysiological situations. J Biomed Biotechnol 2012:156795 Semenza GL, Jiang BH, Leung SW et al (1996) Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271(51):32529–32537 Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF (1991) Role of cell-surface lysines in plasminogen binding to cells: identification of α-enolase as a candidate plasminogen receptor. Biochemistry 30(6):1682–1691 Menzhinskaya IV, Pavlovich SV, Vanko LV et al (2023) Clinical Significance of Serum Autoantibodies to Endometrial Antigens, α-Enolase and Hormones in Non-Invasive Diagnosis and Pathogenesis of Endometriosis. Int J Mol Sci 24(21):15578 Zeng Y, Yin F (2024) KAT2A-mediated succinylation modification of ENO1 promotes the invasive and proliferative phenotype of ectopic endometrial stromal cells. Front Pharmacol 15:1381551 Pergialiotis V, Lagkadas A, Giannakopoulos A et al (2023) Urocortin as a biomarker in endometriosis: a systematic review. Eur J Obstet Gynecol Reprod Biol 280:1–8 Huang Q, Liu Y, Zhang S et al (2024) MMP-9 as a clinical marker for endometriosis: a meta-analysis and bioinformatics analysis. Front Endocrinol 15:1475531 Chen Y, Fang L, Cui X et al (2014) Elevated urinary enolase I levels in patients with endometriosis. Biomarkers 19(1):16–20 Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioural, and biomedical sciences. Behav Res Methods 39(2):175–191 Cohen J (1988) Statistical Power Analysis for the Behavioural Sciences, 2nd edn. Lawrence Erlbaum Associates, Hillsdale, NJ Buck Louis GM, Hediger ML, Peterson CM et al (2011) Incidence of endometriosis by study population and diagnostic method: the ENDO study. Fertil Steril 96(2):360–365 Hosmer DW, Lemeshow S, Sturdivant RX (2013) Applied Logistic Regression, 3rd edn. Wiley, Hoboken, NJ Carrarelli P, Luddi A, Funghi L et al (2016) Urocortin and corticotropin-releasing factor receptor type 2 mRNA are highly expressed in deep infiltrating endometriotic lesions. Fertil Steril 105(5):1290–1296 Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721–732 Iyer NV, Kotch LE, Agani F et al (1998) Cellular and developmental control of O₂ homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12(2):149–162 Yang J, Liao S, Yang H et al (2019) Reciprocal regulation between miRNAs and HIF-1α in human cancers: complexity, dynamics and clinical implications. RNA Biol 16(6):706–721 Li Y, Zhang H, Guo J et al (2025) MMP-2 and MMP-9 in endometriosis: roles in invasion and angiogenesis. Biomed Rep 22(1):1–10 Trayhurn P, Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92(3):347–355 Zhang L, Xiong W, Li N et al (2017) Estrogen stabilises hypoxia-inducible factor 1α through G-protein-coupled estrogen receptor 1 in eutopic endometrium of endometriosis. Fertil Steril 107(2):439–447 Yong Q, Guo Y, Li X et al (2017) Association between body mass index and endometriosis risk: a meta-analysis. Oncotarget 8(28):46928–46936 Hediger ML, Hartnett HJ, Louis GM (2005) Association of endometriosis with body size and figure. Fertil Steril 84(5):1366–1374 Xu Y, Chen L, Wang M et al (2026) Combined serum biomarker panel for non-invasive diagnosis of endometriosis. Reprod Biomed Online 52(1):103–112 Rokhgireh S, Hoseini Rashidi B, Bagheri M et al (2020) The Diagnostic Accuracy of Combined Enolase/Cr, CA-125, and CA19-9 in the Detection of Endometriosis. Dis Markers 2020:5208279 Nisenblat V, Prentice L, Bossuyt PM, Farquhar C, Hull ML, Johnson N (2016) Combination of the non-invasive tests for the diagnosis of endometriosis. Cochrane Database Syst Rev 7(7):CD012281 Karakus S, Sancakdar E, Akkar O, Yildiz C, Demirpence O, Celik HT (2016) Elevated serum levels of HIF-1α in patients with endometriosis. Clin Lab 62(12):2519–2523 Tolu Cenk S, Kara M, Uysal S (2025) Serum HIF-1α levels in endometriosis patients. J Obstet Gynaecol Res 51(1):e16150 Zhang L, Liu Y, Wang S et al (2018) Hypoxia-inducible factor-1α expression and its clinical significance in endometriosis. Arch Gynecol Obstet 297(6):1487–1492 Wykes CB, Clark TJ, Khan KS (2004) Accuracy of laparoscopy in the diagnosis of endometriosis: a systematic quantitative review. BJOG 111(11):1204–1212

Acknowledgements

The authors gratefully acknowledge the medical and nursing staff at the Maternity and Children Teaching Hospital in Babylon, the Maternity and Obstetrics Hospital in Karbala, and Al-Kafeel Super Speciality Hospital for their invaluable assistance with patient recruitment and sample collection. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Author information Authors and Affiliations Contributions ZBJ conceptualized the study, performed the biochemical assays, and drafted the manuscript. KAS supervised the biochemical analysis and contributed to the interpretation of data. SFA conducted the statistical analysis and critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript. Corresponding author Ethics declarations Ethics approval and consent to participate The study protocol was approved by the Institutional Ethics Committee of the College of Medicine, University of Babylon (Ref. No. 5/65, September 18, 2025). Written informed consent was obtained from all participants prior to enrolment and blood collection, in strict accordance with the ethical standards of the Declaration of Helsinki. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Additional information Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Supplementary Information Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. About this article Cite this article Jabbar, Z.B., Al-Shaikh, S.F. & Shemran, K.A. Correlation between serum Urocortin-1 and α-Enolase in endometriosis: insights into a potential stress–metabolism signalling axis. Middle East Fertil Soc J 31, 83 (2026). https://doi.org/10.1186/s43043-026-00338-w Received: Accepted: Published: Version of record: DOI: https://doi.org/10.1186/s43043-026-00338-w

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (29)

Source provenance

openalex
last seen: 2026-11-16T06:03:07.005966+00:00
License: CC0 · commercial use OK